MedicineNet.com
About Us | Privacy Policy | Site Map
November 22, 2009
MedicineNet home Picture Slideshows Diseases and conditions Symptoms and signs Procedures and tests Medications Health and Living Picture Image Collection MedTerms medical dictionary
Font Size
A
A
A

Overdose Warning for Pain Drug Propoxyphene

FDA Strengthens 'Black Box' Warning and Orders More Studies for Painkiller Propoxyphene, Sold Generically and as Darvon and Darvocet

By Miranda Hitti
WebMD Health News

Reviewed By Louise Chang, MD

July 7, 2009 -- The FDA today ordered new warnings about overdose risk for the pain medication propoxyphene, which is sold generically and under the brand names Darvon and Darvocet.

The FDA is requiring the "black box" warning -- the FDA's sternest warning -- on drugs containing propoxyphene to emphasize the potential for overdose. The FDA also ordered more studies of propoxyphene's safety.

But the FDA didn't ban propoxyphene, although an advisory committee narrowly voted in January to recommend such a ban.

The FDA often follows the advice of its advisory committees, but it's not required to do so.

In this case, the FDA decided that drugs containing propoxyphene are an "acceptable option for mild to moderate pain when taken as directed," Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research, said today in a news conference.

Propoxyphene has been on the market since 1957. From 1969 to 2005, the FDA got 91 reports of deaths in people taking propoxyphene. Most of those deaths were drug overdoses and suicide attempts, often involving multiple drugs, Gerald Dal Pan, MD, MPH, director of the FDA's Office of Surveillance and Epidemiology, said during today's news conference.

Woodcock said the FDA took another look at propoxyphene after the nonprofit group Public Citizen filed a petition in 2006 calling for the drug's ban. Woodcock also noted that the FDA has been reviewing other types of pain relievers, including last week's meeting on acetaminophen safety.

SOURCES: Janet Woodcock, MD, director, Center for Drug Evaluation and Research, FDA. Gerald Dal Pan, MD, MPH, director, Office of Surveillance and Epidemiology, FDA. News release, FDA. FDA: "Propoxyphene Questions and Answers."

©2009 WebMD, LLC. All Rights Reserved.


Printer-Friendly Format  |  Email to a Friend



Women's Health

Find out what women really need.


Are you Depressed? Take the Quiz

Your Guide to Symptoms & Signs: Pinpoint Your Pain





Overdose Warning for Pain Drug Propoxyphene Related Articles







Health categories:

Slideshows | Diseases & Conditions | Symptoms & Signs | Procedures & Tests | Medications | Health & Living | News & Views | Medical Dictionary

Popular health centers:

Allergies | Arthritis | Cancer | Diabetes | Digestion | Healthy Kids | Heart | Men's Health | Mental Health | Women's Health | More...

Publications:

ePublications (PDFs) | XML News via RSS | Audio Podcasts | Email Newsletters

MedicineNet.com:

About Us | Privacy Policy | Site Map | WebMD® | Medscape® | eMedicine® | eMedicineHealth® | RxList®

This website is certified by Health On the Net Foundation. Click to verify. This site complies to the HONcode standard for trustworthy health information:
verify here.

©1996-2009 MedicineNet, Inc. All rights reserved. Notices and Legal Disclaimer.
MedicineNet does not provide medical advice, diagnosis or treatment. See additional information.